Last reviewed · How we verify
NCT06859593
Upper Extremity Exercise Capacity Of Breast Cancer
trial testing Upper Extremity Exercise Capacity, 6-Minute Pegboard And Ring Test in Breast Cancer Survivor in 48 participants. Completed in 1 June 2025.
1 May 2025
Quick facts
| Lead sponsor | Hacettepe University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 1 March 2025 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 June 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Upper Extremity Exercise Capacity, 6-Minute Pegboard And Ring Test
Conditions studied
- Breast Cancer Survivor — all drugs for Breast Cancer Survivor →
- Healty Controls — all drugs for Healty Controls →
Sponsor
Hacettepe University
Who can join
Adults 18 to 65, female only, with Breast Cancer Survivor or Healty Controls. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Breast cancer is one of the most common cancers among women worldwide, with an incidence rate of up to 16%. Although survival can be improved with early diagnosis and more effective therapies, physical complications such as lymphedema, upper extremity dysfunction and chronic pain are common during and/or after breast cancer treatments. In addition, lymphedema can cause symptoms such as decreased muscle strength and range of motion of the upper extremity, pain and fatigue, resulting in activity limitations and decreased functional level of the upper extremity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06859593
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer Survivor
Currently open trials in the same condition.
- NCT07015944 — Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in Pakistan · NA · recruiting
- NCT07083518 — Transcranial Direct Current Stimulation for Cancer-related Cognitive Impairment in Breast Cancer Survivors · NA · active not recruiting
- NCT06938555 — The RolE of Prolonged Nightly faSTing to Improve Sleep and cOgnition in bREast Cancer Survivors · NA · recruiting
- NCT06671730 — Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast · NA · recruiting
Other Hacettepe University trials
Trials by the same sponsor.
- NCT07522060 — Early Functional Response as a Predictor of Clinical Outcomes in Hand Rehabilitation: A Prospective Feasibility Study Us · not yet recruiting
- NCT07390162 — The Effect of Changes in the Frequency of Endotracheal Tube Repositioning in Intensive Care Units on the Prevention of O · NA · not yet recruiting
- NCT07579676 — DEVELOPMENT AND PSYCHOMETRIC EVALUATION OF THE NEUROCOGNITIVE UPPER EXTREMITY TESTS: A RELIABILITY AND VALIDITY STUDY · not yet recruiting
- NCT07524842 — Clinical Performance of Three Different Restorative Materials · NA · not yet recruiting
- NCT07439861 — The Effect of Cognitive Dual-Task on Athletic Performance Parameters in Volleyball Players With and Without Chronic Ankl · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06859593 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hacettepe University
- Last refreshed: 9 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06859593.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing